Clinical trial
First Line Chemotherapy Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
NCT00308750 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00308750 |
|---|---|
| Title | First Line Chemotherapy Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) |
| Official title | A Randomized, Open-label Phase II Study of Pemetrexed (Alimta) Plus Carboplatin With or Without Enzastaurin Hydrochloride, or Docetaxel Plus Carboplatin as First Line Treatment in Patients With Advanced Stage Non-small Cell Lung Cancer (NSCLC) |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non-Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | enzastaurin, pemetrexed, docetaxel, carboplatin |
| Enrollment | 218 |
| Start date | Mar 1, 2006 |
| Primary completion | Jul 1, 2009 |
| Completion | Jul 1, 2009 |
| First posted | Mar 30, 2006 |
| Last update posted | May 13, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: